BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27984766)

  • 1. Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.
    Jung J; Lee HJ; Kim SM; Kang YA; Lee YS; Chong YP; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Lee JH; Lee JH; Lee KH; Kim SH
    J Clin Virol; 2017 Feb; 87():5-11. PubMed ID: 27984766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data.
    Bae S; Jung J; Kim SM; Kang YA; Lee YS; Chong YP; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Lee JH; Lee JH; Lee KH; Kim SH
    Immune Netw; 2018 Apr; 18(2):e2. PubMed ID: 29732231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study.
    Kim SH; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Han DJ
    Infect Chemother; 2015 Jun; 47(2):105-10. PubMed ID: 26157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
    Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
    BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
    Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
    PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D; Small A; Borrows R; Ball S
    PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
    Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
    J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
    Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
    Abu-Khader A; Krause S
    Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
    Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
    J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T; Stein M; Reinke P
    Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
    J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
    PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomonitoring via ELISPOT Assay Reveals Attenuated T-Cell Immunity to CMV in Immunocompromised Liver-Transplant Patients.
    Traska AK; Nowacki TM; Vollenberg R; Rennebaum F; Meier JA; Schomacher T; Reinartz Groba SN; Fischer J; Trebicka J; Tepasse PR
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
    Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
    Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.
    Camargo JF; Komanduri KV
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):233-238. PubMed ID: 28641094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.